Truncated EGF receptor
AssigneesCommonwealth Scientific and Industrial Research Organisation, Ludwig Insitutute for Cancer Research
InventorsColin Ward, Neil McKern, George Lovrecz, Robert Jorissen, Thomas Garrett, Thomas Elleman, Antony Burgess, Timothy Adams, Teresa Domagala, Edouard Nice
Life of this patent
Estimating the term…
Abstract
The present invention relates to truncated EGF receptor molecules that exhibit increased binding affinities for EGFR ligands such as EGF and TGF1. The present invention also relates to methods of screening for EGF receptor ligands and methods of treatment which involve the use of these molecules.
Claims26
A truncated epidermal growth factor receptor (EGFR) ectodomain comprising at least residues 1-492 of ErbB1 or equivalent residues of another member of the EGFR family, the truncated EGFR ectodomain lacking at least the third to seventh modules of the CR2 domain such that the truncated EGFR ectodomain has an increased binding affinity for at least one EGFR ligand when compared to the full length EGFR ectodomain.
Dependencies are inferred from the claim text.